Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
暂无分享,去创建一个
G. Remuzzi | F. Eitner | C. Legendre | J. Nürnberger | T. Feldkamp | N. Sheerin | D. Fouque | A. Trivelli | C. Licht | Y. Lebranchu | L. Greenbaum | C. Legendre | C. Mariat | R. Furman | B. Moulin | D. Cohen | C. Loirat | D Fouque | G Remuzzi | L. Zimmerhackl | P. Muus | D. Karpman | J. Menne | K. Douglas | C Loirat | B Moulin | J Menne | C M Legendre | C Licht | P Muus | L A Greenbaum | S Babu | C Bedrosian | C Bingham | D J Cohen | Y Delmas | K Douglas | F Eitner | T Feldkamp | R R Furman | O Gaber | M Herthelius | M Hourmant | D Karpman | Y Lebranchu | C Mariat | J Nürnberger | M Ogawa | T Richard | R Sberro-Soussan | B Severino | N S Sheerin | A Trivelli | L B Zimmerhackl | T Goodship | T. Goodship | R. Sberro-Soussan | Y. Delmas | M. Herthelius | M. Hourmant | C. Bingham | M. Ogawa | O. Gaber | S. Babu | Lawrence Greenbaum | B. Severino | C. Bedrosian | T. Richard | Yahsou Delmas
[1] K. Amann,et al. Thrombotic microangiopathy: new insights , 2010, Current opinion in nephrology and hypertension.
[2] R. Rabin,et al. EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.
[3] G. Escolar,et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. , 2010, Transplantation.
[4] J. D. Harris,et al. ROYAL DEVON AND EXETER HOSPITAL, EXETER. , 1904 .
[5] S. D. Subba Rao,et al. Atypical hemolytic uremic syndrome. , 2002, Indian pediatrics.
[6] A. Garnier,et al. Plasmatherapy in atypical hemolytic uremic syndrome. , 2010, Seminars in thrombosis and hemostasis.
[7] V. Frémeaux-Bacchi,et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies , 2012, Nature Reviews Nephrology.
[8] M. Noris,et al. Complement and the atypical hemolytic uremic syndrome in children , 2008, Pediatric Nephrology.
[9] Yoshihiro Kokubo,et al. FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay , 2005, British journal of haematology.
[10] W. Gregory,et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. , 2010, Blood.
[11] G. Remuzzi,et al. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. , 2009, Journal of the American Society of Nephrology : JASN.
[12] N. Kamar,et al. Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] G. Remuzzi,et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[14] Colin H. Wilson,et al. Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] R. Brodsky,et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.
[16] G. Remuzzi,et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. , 2006, Blood.
[17] N. Young,et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.
[18] K. Kliche,et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. , 2010, The New England journal of medicine.
[19] P. Zipfel,et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[20] C. Licht,et al. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. , 2013, Molecular immunology.
[21] L. Matis,et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. , 1995, The Journal of clinical investigation.
[22] M. López-Trascasa,et al. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] G. Ardissino,et al. Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] C. Legendre,et al. New insights into postrenal transplant hemolytic uremic syndrome , 2011, Nature Reviews Nephrology.
[25] B. Hurault de Ligny,et al. Safety and Long‐Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic–Uremic Syndrome , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[26] L. Rostaing,et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[27] C. Loirat,et al. Management of hemolytic uremic syndrome. , 2012, Presse medicale.
[28] P. Zipfel,et al. Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.
[29] D. Geary,et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. , 2009, Blood.
[30] R. Gruppo,et al. Eculizumab for congenital atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.
[31] N. Young,et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. , 2008, Blood.
[32] Giuseppe Remuzzi,et al. Atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.
[33] P. Zipfel,et al. Thrombotic microangiopathies: new insights and new challenges , 2010, Current opinion in nephrology and hypertension.